Earlier today, Justice M.S. Sanklecha of the Bombay High Court dismissed a challenge by Bayer AG to the IPAB’s decision to grant Natco a compulsory license to manufacture and distribute a generic version of Bayer’s patented kidney cancer drug, Nexavar. As per the Mint report, Justice Sanklecha stated, “We don’t see a reason to interfere with the order passed by IPAB and, therefore, the case is dismissed.” In upholding the Nexavar compulsory license, generic versions of the drug can continue to...
↧